Amgen (AMGN), Provention Bio (PRVB) Announce Co-Development Collaboration In Celiac Disease
Tweet Send to a Friend
Amgen (NASDAQ: AMGN) and Provention Bio, Inc. (NASDAQ: PRVB), a clinical-stage biopharmaceutical company focused on immune-mediated diseases, today announced a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
